Laurent Hallut Wealth Management Makes New Investment in Novavax, Inc. (NASDAQ:NVAX)

Laurent Hallut Wealth Management bought a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the beginning of the third quarter, according to its most recent filing with the Financial Conduct Authority. The institutional investor bought on Friday – 4th of September, 80,500 shares of the biopharmaceutical company’s stock, valued at approximately $6,600,000 or $82 per share.

Several other hedge funds have also modified their holdings of NVAX. Nisa Investment Advisors LLC boosted its holdings in shares of Novavax by 19.7% during the second quarter. Nisa Investment Advisors LLC now owns 455 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 75 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of Novavax by 36.8% during the second quarter. Flagship Harbor Advisors LLC now owns 390 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 105 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Novavax by 315.8% in the second quarter. Steward Partners Investment Advisory LLC now owns 395 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 300 shares during the period. Global Retirement Partners LLC acquired a new stake in Novavax in the second quarter worth approximately $25,000. Finally, Central Bank & Trust Co. acquired a new stake in Novavax in the second quarter worth approximately $33,000. 51.86% of the stock is owned by institutional investors and hedge funds.

NVAX has been the topic of several recent analyst reports. BidaskClub downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. upgraded shares of Novavax from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $105.00 to $275.00 in a report on Wednesday, August 5th. Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating and set a $145.00 price objective for the company. in a report on Tuesday, August 25th. HC Wainwright upped their price objective on shares of Novavax from $101.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, B. Riley reiterated a “buy” rating and issued a $257.00 price objective on shares of Novavax in a report on Monday, August 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $139.44.

Leave a Reply

Your email address will not be published. Required fields are marked *